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Abstract 
Introduction. Kidney tumours are frequently characterised by hypoxic conditions due to a local imbalance 
between oxygen (O2) supply and consumption. Hif1-α regulates angiogenesis, tumour growth, tumour 
progression, metastatic spread, and glucose metabolism by acting as a transcription factor for relevant genes. 
Here, we describe an immunohistochemical study of Hif1-α, a comprehensive computational study of Hif1-α 
interacting proteins (HIPs), an analysis correlating expression levels of Hif1-α with upstream and downstream 
proteins, and an analysis of the utility of Hif1-α for prognosis in a cohort of patients with renal cell 
carcinoma. 
Materials and methods. The patient cohort included 80 patients. For immunohistochemistry evaluation, tissue 
microarrays were constructed. The IntAct, MINT, and BOND databases were used for the HIP approach. The 
Kruskal–Wallis test was used for comparing protein expression with pathology measurements. Correlation 
was expressed as the Pearson coefficient. 
Results. Hif1-α expression correlates significantly with the “clear” histological subtype of renal cell 
carcinoma (p < 0.01). The samples with the worst prognoses related to the pathological variables analysed 
showed the highest levels of Hif1-α expression. Significant correlations were found with Bcl-2, CAIX, C-kit, 
EGFR, TGF-β, proteins of the VEGF family, proteins related to differentiation (such as Notch1 and Notch3) 
and certain metabolic enzymes. Bioinformatic analysis suggested 45 evidence-based HIPs and 4 complexes 
involving protein Hif1-α. 
Conclusions. This work summarises the multifaceted role of Hif1-α in the pathology of renal cell carcinomas, 
and it identifies HIPs that could help provide mechanistic explanations for the different behaviours seen in 
tumours. 
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Introduction 
Renal cancer accounts for 3 % of all malignant tumours. Carcinomas arising from the renal 
epithelium account for approximately 85 % of renal tumours. The major risk factors include 
smoking (responsible for 24–30 % of all cases of renal cell carcinoma), obesity, and various 
environmental and occupational factors. 
 
Renal cell carcinoma (RCC) is a heterogeneous group of cancers, but 60–80 % of cases belong 
to the “clear” histological subtype. Other histology subtypes include the “papillary” and 
“chromophobe” subtypes. 
 
These different subtypes represent very different diseases that are not strictly variants of RCC. 
Understanding histological subtypes and associated gene alterations has allowed the development 
of targeted therapeutic agents. 
 
Much research has focused on finding reliable indicators of the underlying biology of RCC. 
With the advancement of technologies that allow probing of the genetic and molecular 
underpinnings of this cancer, many discoveries have led to major innovations in RCC treatment, 
including a panel of molecularly targeted drug therapies. 
 
Like many solid tumours, kidney tumours are frequently characterised by hypoxic conditions, 
which result from a local imbalance between oxygen (O2) supply and consumption [1]. Indeed, 
hypoxia and compensatory hyperactivation of angiogenesis are thought to be particularly 
important in RCC compared to other tumour types, given the highly vascularised nature of kidney 
tumours and the specific association of mutation in Von Hippel-Lindau (VHL), a critical regulator 
of the hypoxic response, with onset of RCC [2]. 
 
Hif1-α regulates angiogenesis, tumour growth, progression, metastatic spread, and glucose 
metabolism by acting as a transcription factor for crucial proteins such as vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor receptor 
(EGFR), insulin-like growth factor (IGF), glucose transporters (GLUT-1), chemokine receptors 
(CXCRs), and carbonic anhydrase IX and XII (CAIX, CAXII). In addition, Hif1-α plays an 
important role in regulating the cell cycle and apoptosis [3, 4]. 
 
Although a relatively infrequent malignancy, kidney cancer has no satisfactory treatment 
options. It would be of great help to be able to diagnose patients on the basis of easily accessible 
biomarkers, potentially identifying the disease early, before it becomes metastatic and while the 
tumour is still resectable. 
 
So there is a need to study the associations between the marker of hypoxia Hif1-α and proteins 
related to the main pathways which feed RCC: angiogenic [(VEGF, vascular endothelial growth 
factor receptor 2 (FLK1) and VHL], apoptotic [tumour protein suppressor p53, B cell lymphoma 2 
protein (BCL-2), Bcl-2-associated X protein (BAX), murine doble minute 2 (MDM2) and 
baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 (SURVIVIN)], differentiation 
(notch receptors referred to NOTCH1-4, and notch ligands DLL1, DLL3-4 and JAGGED1), 
metabolic (GLUT1-5 and CAIX), proliferation and/or invasiveness [epidermal growth factor 
receptor (EGFR), PDGFR-α, PDGFR-β, proto-oncogene c-Kit (C-KIT) and transforming growth 
factor (TGF-α)] and proteins related to the inflammatory process as TGF-β. 
 
In this report, we present an immunohistochemical (IHC) study of Hif1-α, undertake a 
comprehensive computational study of Hif1-α interacting proteins (HIPs), correlate expression 
levels of HIPs with upstream and downstream proteins, and evaluate the utility of Hif1-α for 
prognosis in a cohort of RCC patients. 
 
The analysis of HIPs is a good way to identify pathways and networks that are altered in RCC, 
which could be useful in the development of diagnostic tests for patients at increased risk for the 
disease, as well as in the development of novel therapeutic approaches for RCC. 
  
Materials and methods 
Patients 
The patient cohort included 80 patients treated with a partial or radical nephrectomy for RCC, 
including chromophobe, papillary and clear cell variants, between 1996 and 2006. IHC studies 
were performed, and clinical data from an established kidney cancer database were reviewed. 
Patients were staged using radiographic studies and postoperative pathological data, according to 
the 1997 tumour-node-metastasis (TNM) criteria proposed by the American Joint Committee on 
Cancer (AJCC). Tumours were categorised using the Fuhrman grading scheme [5]. The patients 
consisted of 53 men and 27 women, aged 34–87 years, with a mean age of 64. There were 57 cases 
of clear cell type RCC (cRCC), 15 cases of chromophobe RCC (chRCC), 6 cases of papillary RCC 
(pRCC), 2 samples classified as “histological type not determined”, and 11 healthy controls. 
Among the RCC patients, 50.6 % had tumours located on their right side, and 49.4 % had tumours 
on the left. Renal pelvic invasion was observed in 11 % of tumours. Only 2.5 % of the cases 
studied showed invasion of lymphatic vessels. We observed renal capsule rupture in 15 % of 
tumours (n = 80). Only one case showed invasion of the veins, being negative 98.8 % for this 
pathological parameter. Renal hilar invasion was seen in 7.3 % of tumours. Tumours ranged from 
2 to 140 cm in length. 
Tissue microarray construction 
Archival tumour specimens from the cohort of 80 patients were obtained from the 
histopathological archives of the Pathology Department of the Modelo Hospital, A Coruña, Spain, 
with the approval of the institutional review board. Written informed consent was obtained from 
all patients. 
 
For IHC evaluation, tissue microarrays (TMA) were constructed using a manual tissue arrayer 
with accessories provided by Durviz. Representative haematoxylin–eosin-stained tumours were 
reviewed to assess the histological type and grade and to identify viable, morphologically 
interesting areas of the specimen. Three cylindrical core biopsies (2 mm in diameter) were taken 
from different sites of each tumour and precisely arrayed in a recipient paraffin tissue microarray 
block to construct a TMA containing 48 samples in a 6 × 8 grid. To serve as controls, 11 
specimens from healthy kidney were also analysed. One pathologist (JM Rois) blinded to the 
pathological data, evaluated immunoreactivity of the TMA. 
Immunohistochemistry and evaluation of expression 
The primary antibodies used are listed in Table 1. IHC technique was carried out as previously 
described [6]. 
  
Table 1. Antibody panel 
Antibody Company Concentration Antigen retrieval Positive control 
     
Hif1-α Abcam 1:1500 Citrate Squamous cell carcinoma 
VHL ABR Ready to use Citrate Healthy kidney 
VEGF Sta Cruz 1:100 Citrate Healthy kidney 
Flk-1 Sta Cruz 1:50 Citrate Healthy kidney 
CAIX Abcam 1:500 Citrate Renal cell carcinoma 
EGFR Dako 1:25 Proteinase K Squamous cell carcinoma 
PDGFR-α Sta Cruz 1:200 Citrate Ovarian carcinoma 
PDGFR-β Serotec 1:40 EDTA Breast carcinoma 
TGF-α LabVision Ready to use Citrate Anterior pituitary 
TGF-β Millipore 1:500 Citrate Colon carcinoma 
C-KIT Dako 1:50 No required GIST 
NOTCH1 Abcam 3 ug/ml Citrate Healthy kidney 
NOTCH2 Lifespan 1:250 Citrate Healthy kidney 
NOTCH3 Sta Cruz 1:50 Citrate Healthy kidney 
NOTCH4 Sta Cruz 1:100 Citrate Healthy kidney 
JAGGED1 Sta Cruz 1:50 EDTA Astrocytoma 
DLL1 Serotec 10 ug/ml EDTA Healthy kidney 
DLL3 Aviva 15 ug/ml Citrate Healthy kidney 
DLL4 Serotec 10 ug/ml Citrate Healthy kidney 
p53 Dako 1:50 EDTA Breast carcinoma 
BAX Abcam Ready to use EDTA Amygdala 
MDM2 Abcam 1.5 ug/ml Citrate Squamous cell carcinoma 
Survivin Sta Cruz 1:100 Citrate Breast carcinoma 
BCL2 Dako 1:75 EDTA Amygdala 
Glut-1 Abcam Ready to use Citrate Healthy esophagus 
Glut-2 Sta Cruz 1:50 Citrate Liver 
Glut-3 Abcam 1:25 Citrate Placenta 
Glut-4 Abcam 1:250 Citrate Hearth 
Glut-5 Abcam 1:250 Citrate Healthy small intestine 
     
 
Antibody expression was evaluated in a blinded fashion to validate the diagnostic morphology 
of each array spot. The evaluation of expression involved determining the site and degree of 
reactivity. The site of reactivity included evaluation of the relevant histological subtype, as well as 
the subcellular localisation. Degree of reactivity included evaluation of maximal staining intensity 
using a 0–3 scale (0, negative; 1, weak; 2, moderate; 3, strong), as well as the percentage of 
positive cells at each stated intensity. 
Bioinformatics tools 
We made use of two databases belonging to The International Molecular Exchange (IMEx) 
consortium, which provides non-redundant, manually annotated data. The number of databases 
providing data may vary, depending on the status of their services. Only those that are active are 
used in this query to study HIPs: 
 
 IntAct: an open-source, open data molecular interaction database and toolkit. Data are 
abstracted from the literature or from direct data depositions by expert curators following a 
deep annotation model providing a high level of detail [7] 
  
 MINT: one of the major public repositories for molecular interactions reported in peer-
reviewed journals [8]. The MINT scoring system reflects the quantity and quality of 
independent supporting evidence stored in the database. The function “Cumulative Evidence” 
is defined as the sum of all supporting evidence weighted by coefficients that reflects the 
confidence in the specific approach. The resulting scores range between 0 and 1, with only well 
supported interactions obtaining a value close to 1. More details and updates are available at 
http://mint.bio.uniroma2.it/mint/doc/MINT-confidence-score.html. 
 BOND: The Biomolecular Object Network Databank is the first open access search resource to 
integrate sequence and interaction information. It serves the interests of the developing global 
interactome effort encompassing the genomic, proteomic and metabolomic research 
communities. It integrates data from several component databases including GenBank and 
BIND (Biomolecular Interaction Network Database) [9]. 
Statistical analysis 
The Kruskal–Wallis test was used for comparing expression among pathological variables. 
Correlation was assessed with the Pearson coefficient. A significance level of 0.05 was used for all 
statistical tests. The statistical package SPSS version 18 was used for the analyses. 
Results 
Immunohistochemical staining of Hif1-α and its correlation with pathological variables 
Anti-HIF1-α is a mouse monoclonal antibody (Abcam), partial recombinant HIF1-α protein. A 
46.3 % of the samples showed a maximum score (+++ average expression cell/tissue from 80 %) 
for this antibody. 27 % of the samples showed a moderate positivity (++). We visualised 
cytoplasm localisation in 100 % of positive samples (see Fig. 1 to visualise IHQ expression profile 
of those proteins with significative statistically association with Hif1-α). Among the pathological 
variables studied, statistical analysis showed that the expression of Hif1-α is related significantly 
with the “clear” histological subtype (p < 0.01). The highest scores occurred in samples from 
tumours with pelvic invasion, broken capsule, and hilar invasion (p = 0.010, p = 0.018, and 
p = 0.014, respectively). In addition, we found a significant relationship between those cases 
showing Hif1-α high expression and were been diagnosed with high node invasion (N) (p < 0.01). 
We found no statistical support to associate this protein with other pathological variables. 
  
 
 
 
Fig. 1. Immunohistochemistry expression profile for those proteins with Hif1-α statistically association in clear cell 
histological type where Hif1-α shows more expression in a significative statistically fashion (p < 0.01) 
Association of Hif1-α protein with other markers 
Statistical significant values of associations between molecular variables are listed in Table 2. 
Analysis of the relationship between Hif1-α and a panel of relevant RCC tumour markers (see 
Table 1) revealed a significant correlation with Bcl-2, CAIX, C-kit, EGFR, TGF-β, proteins of the 
VEGF family, proteins related to differentiation, such as Notch1 and 3 and DLL3 and 4, and 
proteins related to fructose uptake such as Glut5. 
Table 2. Statistically significant correlations between Hif1-α and other biomarkers using Pearson’s correlation coefficient test 
             
HIF1-α Pearson’s correlation N = 80 
FLK1 
-, 448 
VEGF 
,277 
CAIX 
,287 
EGFR 
,291 
CKIT 
-,429 
TGFΒ 
,668 
NOTCH1 
-,529 
NOTCH3 
,365 
DLL3 
,268 
DLL4 
,329 
GLUT5 
,521 
BCL2 
-,664 
P < 0.01 P = 0.014 P = 0.010 P = 0.009 P < 0.01 P < 0.01 P < 0.01 P = 0.001 P = 0.016 P = 0.003 P < 0.01 P < 0.01 
             
 
 
 
Identification of Hif1-α interacting proteins with bioinformatics tools 
The IntAct website allows searches to be performed using the Molecular Interaction Query 
Language (MIQL). This provides a set of predefined fields that can be combined, allowing 
complex queries using Boolean logic. Once a query has been submitted to the website, the 
“Interactions” tab automatically opens and presents the list of interactions matching the query. We 
used the field for Advanced Search to submit the query “HIF1A AND Homo sapiens”. We 
obtained 0 binary interactions in IntAct, but our query matched 55 interaction entries from 1 other 
IMEx database called MINT (Fig. 2) and 1,215 interaction evidences from 6 other databases: 
APID (134), BIND (13), Drug Bank (3), iRefIndex (596) and STRING (469). 
 
 
 
Fig. 2. List of proteins discharged by the database MINT after submitting the query “HIF1A AND Homo sapiens”. X (red) 
identifies proteins linked to a disease. direct. Direct interaction, ass. physical association, coloc. colocalization, enz. 
enzymatic reaction, complex. interaction with more participants, and HT. high throughput experiments (more than 50 
interactions) 
The list of proteins from the program output, the scoring system, based on both, experimental 
data and literature citation is shown in Fig. 2. It contains 25 human proteins and a protein from 
Hepatitis B virus. The protein orthologue for Tsga10 in Homo sapiens is TSGA10 (Q9BZW7), 
which prevents nuclear localisation of Hif1-α [10]. Those that show more evidence of interaction 
have scores closer to 1. In our case, the highest scoring entries are histone acetyltransferase p300 
(EP300, score = 0.85) and Egl nine homologue 1 (EGLN1, score = 0.81). EP300 functions as a 
histone acetyltransferase and regulates transcription via chromatin remodelling. It acetylates all of 
the four core histones found in nucleosomes. Histone acetylation serves as an epigenetic tag for 
transcriptional activation. It also binds to and may be involved in the transforming capacity of the 
adenovirus E1A protein. It mediates cAMP gene regulation by binding specifically to 
phosphorylated CREB protein. In the case of HIV-1 infection, it is recruited by the viral protein 
Tat and regulates Tat’s transactivating activity, and it may help to induce chromatin remodelling 
of proviral genes. Defects in EP300 may play a role in epithelial cancer. The interactions provided 
by the MINT website include 4 based on direct interaction between Hif1-α and EP300, and the 
other 4 evidence interactions indicate physical association between these proteins. EGLN1 
catalyses the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) 
alpha proteins. It hydroxylates Hif1-α at ‘Pro-402’ and ‘Pro-564’, and it hydroxylates prolines in 
Hif-2α. It functions as a cellular oxygen sensor and, under normoxic conditions, targets Hif 
through hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination 
complex. Defects in EGLN1 are the cause of erythrocytosis familial type 3 (ECYT3). For this 
protein we found 4 supported interactions based on 2 physical associations and 2 enzymatic 
reactions. The list also highlights proteins related to tumour diseases, such as MTA1, a component 
of the chromatin remodelling complex. MTA1 is upregulated in many carcinomas [11]. VHL also 
appears on the list; somatic mutations in renal cell carcinomas occur in the VHL gene. Von 
Hippel-Lindau syndrome is a dominantly inherited familial cancer syndrome predisposing carriers 
to a variety of malignant and benign neoplasms, most frequently retinal, cerebellar, and spinal 
haemangioblastoma, RCC, pheochromocytoma, and pancreatic tumours. The evolutionarily 
conserved VHL gene encodes 2 protein products, a 30-kD full-length form (p30) and a 19-kD 
form (p19). The protein products of the VHL gene play a role in the oxygen-sensing pathway, in 
microtubule stability and orientation, tumour suppression, cilia formation, regulation of 
senescence, cytokine signalling, collagen IV regulation, and assembly of a normal extracellular 
fibronectin matrix [12]. ARD1A is a protein acetyltransferase in mammalian cells that acts by 
binding Hif1-α to regulate its stability. Also, ARD1A-mediated acetylation enhances the 
interaction of Hif1-α with VHL and Hif1-α ubiquitination, suggesting that the acetylation of Hif1-
α by ARD1A is critical to proteasomal degradation. The role of ARD1A in the acetylation of Hif1-
α provides a key regulatory mechanism underlying Hif1-α stability [13]. CREBBP is another 
protein on the list; when cellular levels of cAMP increase, a cascade of events leads to the 
induction of genes that contain cis-regulatory elements called cAMP-response elements (CREs). 
Elevated cAMP levels cause stimulation and nuclear translocation of protein kinase A, which 
activates the transcription factor CREB (CRE-binding protein) by phosphorylating it at a single 
residue, serine-133. The recurring translocation t(11; 16) (q23; p13.3) has been observed only in 
cases of acute leukaemia or myelodysplasia secondary to therapy with drugs targeting DNA 
topoisomerase II [14]. HSP90AA1 and HSP90AB1 are highly conserved molecular chaperones 
that have key roles in signal transduction, protein folding, protein degradation, and morphological 
evolution. HSP90 proteins normally associate with other co-chaperones and play important roles 
in folding newly synthesised proteins or stabilising and refolding denatured proteins after stress. 
There are 2 major cytosolic HSP90 proteins: HSP90AA1, an inducible form, and HSP90AB1, a 
constitutive form. HSP90 is a molecular chaperone that plays a key role in the conformational 
maturation of oncogenic signalling proteins, including HER2/ERBB2, AKT, RAF1, BCR-ABL, 
and mutated p53. Tumour cells could contain HSP90 complexes in an activated, high-affinity 
conformation that facilitates malignant progression, which may represent a unique target for 
cancer therapeutics [15, 16]. The transcription factor SP1 is a DNA-binding protein that interacts 
with a variety of gene promoters containing GC-box elements. Overexpression of human SP1 
induced apoptosis in all mouse and hamster cell lines tested. The apoptotic pathways induced by 
SP1 overexpression were cell type specific and required the SP1 DNA-binding domain [17]. 
CUL2 specifically associates with the trimeric VHL-elongin B-elongin C (VBC) complex in vitro 
and in vivo. This association was disrupted by mutations in VHL that disrupt elongin binding. 
Nearly 70 % of the naturally occurring cancer-disposing mutations in VHL abrogate elongin 
binding, suggesting that binding to elongin-CUL2 complexes contributes to the ability of VHL to 
suppress tumour growth in vivo. CUL2 is suggested as a candidate tumour-suppressor gene [18]. 
HDAC1,4,5 histones, nuclear proteins that bind DNA and form nucleosomes, are directly involved 
in both the packaging of DNA into chromosomes and the regulation of transcription. Histone 
acetylation/deacetylation is a major factor in regulating chromatin structural dynamics during 
transcription. HDAC1 physically interacts and cooperates with RB1 (retinoblastoma tumour-
suppressor protein). Deacetylation of p53 is mediated by a HDAC1-containing complex. The 
HDAC1/HDAC2 complex is associated with cancer-causing chromosomal translocations [19]. 
HDAC1 is a direct target of miR449A, which regulates cell growth and viability of prostate cancer 
cells in part by repressing expression of HDAC1 [20]. EST database analysis suggested that 
HIF1AN is expressed in multiple cell types. HIF1AN interacts with Hif-1-α and VHL to mediate 
repression of Hif-1 transcriptional activity [21]. SSX4B, fusion genes identified in synovial 
sarcoma represent a situation in which several members of a gene family have fused to a single 
partner gene and associated with the same malignant disease. The t(X; 18) (p11.2; q11.2) 
translocation is closely associated with the development of synovial sarcoma. SUMO proteins, 
such as SUMO3, and ubiquitin post-translationally modify numerous cellular proteins and affect 
their metabolism and function. However, unlike ubiquitination, which targets proteins for 
degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, 
transcriptional regulation, apoptosis, and protein stability. 
 
Figure 3 outlines HIF1-α binary interactions, as well as those of EP300. MINT does not show 
binary interactions in the case of EGLN1. The scoring system is an effective tool for filtering 
interactions. In Fig. 4 we have displayed all of the proteins that, according to the MINT database, 
interact with the proteins participating in the Hif1-α signalling pathway. 
 
 
 
Fig. 3. Hif1-α and EP300 evidence-based binary interactions. The figure shows the complexity of the system since some of 
the proteins that are interacting with Hif1-α are in turn interacted with one another and so on 
 
 
 
Fig. 4. Hif1-α signalling pathway obtained by MINT database 
To confirm and extend the results obtained through the MINT database, we conducted a search 
through the Biomolecular Object Network Databank (BOND). The BOND interface provides a 
sophisticated way to perform cross-database queries of available sequence, interaction, complex, 
and pathway information. In the “Advanced Field Specific Search” section, we ran a query with 
the term “HIF1A AND Homo sapiens” which returned 41 interactions and 4 complexes. The new 
proteins that have evidence-based interactions with the protein Hif1-α are the following: RB1 
retinoblastoma 1, EPO erythropoietin precursor, VEGF vascular endothelial growth factor, ATF2 
activating transcription factor 2, c-Jun jun proto-oncogene, HNF-4-α hepatocyte nuclear factor 4, 
alpha, MSH6 mutS homologue 6, MSH2 mutS homologue 2, CDKN1A CDK-interacting protein 1, 
ARNT aryl hydrocarbon receptor nuclear translocator, p53 tumour protein p53, PHD2 egl nine 
homologue 1, TAF1 transcription initiation factor TFIID subunit 1, Jab1 COP9 constitutive 
photomorphogenic homologue subunit 5, PHD3 egl nine homologue 3, ARNT2 aryl hydrocarbon 
receptor nuclear translocator 2, HSPCA heat shock protein HSP 90-alpha, p14ARF cyclin-
dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), HPH-2 egl ninehomologue 1, and 
OS-9 osteosarcoma amplified 9, endoplasmic reticulum lectin. With regard to the formation of 
complexes, the program showed us 4 complexes: (1) Hif1-α and ARNT bind to form a Hif1-
α/ARNT heterodimer, which is present in increased amounts in hypoxia; (2) the Hif1-α-OS-9-
PHD2 was isolated by a coimmunoprecipitation assay; (3) the Hif1-α-OS-9-PHD3 complex was 
isolated by a GST pull-down assay; and finally (4) Hif1-α and Hif1-β interact to form a complex. 
  
Discussion 
In this study of RCC, there are four main findings. First, the expression of Hif1-α is 
characteristic of the clear RCC histological subtype. Second, higher intracellular levels of Hif1-α 
are detected in cases with renal pelvis invasion, renal broken capsule and renal hilar invasion. 
Third, increases in the number of involved nodes (N) coincide with a greater cytoplasmic 
localisation of Hif1-α in tumour cells. Last, IHC shows that levels of Hif1-α protein are correlated 
with known markers consequence of its activity as transcriptional factor as CAIX, VEGF, and its 
receptor Flk-1; differentiation markers such as Notch1, 3 and their ligands DLL3 and DLL4; 
markers of invasiveness, proliferation or inflammation such as c-Kit, EGFR and TGF-β, markers 
associated with metabolic processes such as Glut5 and, finally, antiapoptotic markers such as Bcl-
2. 
 
Hif1-α expression is affected by oxygen concentration, VHL status, and the activity of 
interrelated molecular pathways such as the mammalian target of rapamycin pathway [22]. Hif1-α 
induces the transcription of several factors including VEGF, PDGF, CXCR, IGF-1, and CAIX 
[23]. 
 
Clear cell RCC had the highest expression of Hif1-α in a study that investigated Hif1-α 
expression in 66 clear cell, 20 papillary, and 6 chromophobe samples by western blot analysis 
[24]. No significant associations were observed between Hif1-α expression and tumour-node-
metastasis stage, grade, tumour size, vein invasion, or DNA ploidy. In contrast with the study 
previously cited and in accordance with our results, other groups identified high Hif1-α expression 
as an adverse prognostic indicator [25, 26]. These disparate finding may be the result of different 
technological and methodological approaches used in each study. 
 
We showed significant correlations between molecules associated with the pathway of 
angiogenesis such as Flk-1, VEGF, CAIX; molecules related to the pathway of 
invasiveness/proliferation or inflammation such as EGFR, c-Kit and TGF-β; molecules belonging 
to the differentiation pathway such as Notch1, Notch3, DLL3 and DLL4; molecules implicated in 
the transport of sugars such as Glut5, and molecules involved in the antiapoptotic response such as 
Bcl-2. 
 
VEGF-A is the strongest proangiogenic factor and exerts its effects via interaction with 
VEGFR-1 and VEGFR-2 (Flk-1). The fact that Hif1-α showed a positive correlation with VEGF in 
our study corroborates the idea that Hif1-α accumulation leads to enhanced transcription of the 
respective DNA segments [23]. Carbonic anhydrases are transmembrane enzymes that play a 
crucial role in the regulation of pH by catalysing the reversible reaction of carbonic acid to carbon 
dioxide and water [27]. Both hypoxia and VHL inactivation lead to increased cellular levels of 
Hif1-α, and subsequently, to an increase in carbonic anhydrases, especially CAIX [28]. 
 
Hif1-α is involved in apoptosis and cell cycle regulation by controlling p53. Hypoxia induces 
apoptosis by increasing the stability of p53 [29]. In our study we found no statistical correlation 
between p53 and Hif1-α, but a negative correlation was found between the key regulator of 
apoptosis Bcl-2 and Hif1-α. 
 
The placement of Hif-1 both upstream and downstream of cancer metabolism results in a feed-
forward mechanism that may play a major role in the development of the invasive, metastatic, and 
lethal cancer phenotype. Hif1-α activates the transcription of SLC2A1 and SLC2A3, which encode 
the glucose transporters Glut1 and Glut3, respectively. Our results indicate that expression of 
Hif1-α is characteristic of clear cell histological type and, in turn, the expression of Hif1-α is 
positively correlated with the expression of glucose transporter Glut5. Glut5 is the sole transporter 
specific for fructose with no ability to transport glucose or galactose. The extensive expression of 
the glucose transporters, and the fact that in most of the clear cell RCC overexpressing Glut5 the 
rate of fructose uptake is exacerbated indicate that fructose may be a preferred substrate providing 
energy required for the growth and proliferation of renal cell carcinoma of the clear cell type. This 
increase of Glut5 could indicate preferential utilisation of fructose by renal cancer cells [30]. 
  
Notch signalling is connected to a wide variety of cellular processes, including cell fate 
specification, cell proliferation, differentiation, apoptosis and the maintenance of stem cells. 
Culture of lung cancer cells [31] or ovarian cancer cells [32] under hypoxia increases Notch 
pathway activation. Low oxygen content also potentiates Notch signalling in melanocytes through 
stabilisation of Hif1-α [33]. Our cohort of RCC samples showed positive statistical correlation 
between Hif1-α-Notch3, DLL3 and DLL4 ligands. In the case of Notch1, the correlation with 
Hif1-α was negative. Understanding the implications of Notch signalling in various tumour types 
will enable the effects of specific Notch signalling effects on tumour angiogenesis and growth to 
be evaluated as a potential for a novel antiangiogenic therapy in the clinic. 
 
The present study demonstrates the activation of EGFR kinase with increasing tissue 
concentration of Hif1-α in RCC. As in other tumour types [34], we found that Hif1-α and EGFR 
are key molecular effectors in the development and progression of RCC, which act in the 
regulation of tumour angiogenesis as well, show a strong relationship with biological behaviour 
and prognosis of renal tumours, especially clear cell RCC, of which Hif1-α overexpression is 
characteristic. 
 
Our results indicate that, in low-Hif1-α tissue, increasing the concentration of Hif1-α increases 
the concentration of c-Kit, and vice versa. Signalling by the receptor for stem cell factor (SCF), c-
Kit, is of major importance for haematopoiesis, melanogenesis and reproduction, and the 
biological responses include proliferation and cell survival. We hypothesised that, because Hif1-α 
is expressed in the clear cell histological subtype and c-Kit is expressed in the chromophobe 
subtype [35], clear cell carcinomas and chromophobe carcinomas may have different signalling 
mechanisms at the angiogenesis and tumour progression level. 
 
Finally, we emphasise that in our cohort of renal tumours the accumulation of Hif1-α 
corresponded to an increase in TGF-β. TGF-β is one of several cytokines that regulate 
angiogenesis. TGF-β can function either as a proangiogenic or antiangiogenic factor in vitro; 
however, the preponderance of evidence supports a proangiogenic role for TGF-β in vivo. Several 
lines of evidence support a prominent role for this cytokine signalling pathway in stimulating 
angiogenesis [36, 37, 38]. TGF-β signalling in endothelial cells is unique in that it can activate two 
distinct pathways: the classical Smad-dependent pathway through TβRII and TβRI to activate 
Smads 2 and 3, and the pathway through TβRII and ALK-1 to activate Smads 1, 5, and 8, which 
are usually activated by the TGF-β superfamily members, the bone morphogenetic proteins. The 
balance of signalling between these pathways regulates endothelial cell biology through the 
activation (increased endothelial cell proliferation and migration) and maturation (decreased 
endothelial cell proliferation and migration) phases of angiogenesis [39]. 
 
As protein–protein interactions are central to most biological processes, the systematic 
identification of all protein interactions is considered a key strategy for uncovering the inner 
workings of a cell. Understanding the large-scale organising principles of protein interaction 
networks is one of the prominent goals of post-genomic biology. Computational tools have 
become critical for the integration, representation and visualisation of heterogeneous biomedical 
data. Furthermore, several bioinformatics methods have been developed to formulate predictions 
about the functional role of genes and proteins, including their role in diseases [40]. Actually, the 
number of protein interaction databases is increasingly extensive, and allows us to use 
bioinformatics tools as IntAct, a database based on scientific publications that did not give us any 
binary interaction for Hif1-α search in Homo sapiens, but that led us to other databases that 
showed our query results. So we focused on the results obtained from MINT as it is another 
database belongs to IMEX consortium. The computational study of Hif1-α interacting proteins we 
have carried out using bioinformatics tools demonstrates the complexity that exists at the cellular 
level, taking into account the complex interaction networks that can surround a single protein. A 
major goal of such computational studies should be to decipher biological functions at the level of 
protein interactions, which may explain cellular behaviours and allow us to further characterise 
new tumour classes within the same histological subtype. 
 
Individualised medicine seeks to identify the molecular basis of an individual patient’s 
response to different therapeutic treatments. Individualised medicine is relevant for diseases such 
as cancer, and it has become a challenge to accomplish more efficient and specific therapeutics. 
An individualised response to treatment could make the difference between therapeutic success 
and failure and could provide a basis for a more individualised prognosis. The use of up-to-date 
“omic” approaches is changing the way we understand modern medicine in terms of drug efficacy, 
toxicity and diagnosis. Results from genetic polymorphism studies, gene and protein expression 
profiling and epigenetic analysis illustrate how pharmacogenomic testing will contribute to the 
goal of individualised medicine. 
 
To achieve the promise of individualised molecular medicine, the application of bioinformatics 
tools to the entire hierarchy of biological system interactions and dynamics will be required. Such 
tools will help to promote the effective discovery, validation and application of new diagnostic and 
treatment strategies in a real-time environment. 
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